ArticleBioscience reports2026
Lipid metabolism as a marker for glioma aggressiveness.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioblastoma (GBM) is the most aggressive type of central nervous system tumor. There have been advances in glioma biology understanding; however, the current therapies are still inefficient. Additionally, new molecular markers are being explored for glioma grading, offering potential for novel diagnostic and drug targets. Considering the important role of lipid metabolism in tumorigenesis, understanding the lipid-related pathways in glioma could lead to new important markers. Here, lipid metabolism was analyzed by integrating two different data sources, the transcriptome data from The Cancer Genome Atlas and experimental data from tumor cells, to investigate how lipid metabolism is regulated in glioma. We compared the expression of 743 lipid-related genes in public RNAseq data of glioma patients (n = 681) to lipidomic analyses of glioblastoma cell lines (A172, U87MG, and T98G). We identified 29 lipid-related genes correlated to prognosis and constructed a risk signature based on these genes. Extracellular matrix-related genes were positively correlated to the risk score. Our findings revealed that aggressiveness is linked to alterations in membrane composition, characterized by an increase in phospholipids, coupled with a decrease in cholesterol and fatty acid unsaturation levels, which impact membrane physical properties. Modulation of critical signaling lipids, specifically sphingolipids, was also observed. Here, we identify lipid markers that may play a significant role in glioma. The converging axis involving sphingomyelinase and sphingosine-1-phosphate, mediated by the actions of sphingomyelinase SMPD1 and sphingosine-kinase SPHK1, emerged as a pivotal factor in glioma. The present study suggests that lipid membrane composition is pivotal for the GBM aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.